A Phase 1/2 interventional study of Remdesivir (RDV) and Placebo in COVID-19, sponsored by Gilead Sciences. Completed at 28 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-03.
Sponsored by Gilead Sciences · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies testing remdesivir in COVID-19 — 6 open to participants now, 9 under way, 3 of them phase 3. remdesivir · COVID-19.
Among the 40 studies testing remdesivir in COVID-19, this one is the 27th largest by enrollment, is one of 27 that started in 2020, is the only one in phase 1/2, and was the 19th registered.
7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.
Browse COVID-19 studies →6 of the 40 studies testing remdesivir in COVID-19 are open now, in 12 countries. Recruiting first, the newest first:
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia · Sites in Spain
Ages 18+
Pfizer · Sites in United States, Argentina, Belgium and 15 more countries
Ages 18+
ANRS, Emerging Infectious Diseases · Sites in France, Italy, Norway
Ages 16+
University of Oxford · Sites in Brazil, Laos, Nepal and 2 more countries
Ages 18–60
Lebanese University · Sites in Lebanon
Ages 18+
By country, each count listing its studies:
remdesivir: first FDA approval 2020 (VEKLURY), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 12 · Phase 3 22 · Phase 4 5
First in 2016; this study’s year is marked. 27 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 156 is above the median of 102 across 4,366 interventional studies indexed under COVID-19.
Median enrollment 283 across the 40 interventional studies. Of the 20 that completed or were terminated, 10 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 40 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
10 studies in COVID-19 by Gilead Sciences: none open now, none under way, none of them phase 3. Of 9 finished, 9 (100%) have results posted.
Among the 10 studies in COVID-19 by Gilead Sciences, this one is one of 5 that started in 2020, is the only one in phase 1/2, and was the 6th registered.
Gilead Sciences’s COVID-19 studies by the year they started, since 2020.
4 of the studies testing remdesivir in COVID-19 that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT07197164Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la CienciaSafety and Effectiveness of a Remdesivir Treatment to Prevent Severe COVID-19 in Kidney Transplant Patients | 2026-12-30 |
| NCT05587894ANRS, Emerging Infectious DiseasesOPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial | 2026-12-31 |
| NCT05041907University of OxfordFinding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) | 2027-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 40 studies testing remdesivir in COVID-19, from their registry updates:
Among Gilead Sciences’s 10 in COVID-19:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to characterize the impact of inhaled remdesivir (RDV) on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load in participants with early stage coronavirus disease 2019 (COVID-19).
This study will have multiple parts: Part A, Part B, and Part C. Part B will be conducted if supported by evaluation in healthy volunteers in another Phase 1a Gilead study (GS-US-553-9018). Participants in Part C will be enrolled after review of preliminary safety and available efficacy data from Parts A and B through at least Day 7.
GS-US-553-9018 is a Phase 1a randomized, blinded, placebo-controlled, single- and multiple-dose study in healthy volunteers to evaluate the safety, tolerability, and pharmacokinetics of remdesivir administered by inhalation.
Key Inclusion Criteria:
Key Exclusion Criteria:
Treatment of COVID-19 with other agents with actual or possible direct antiviral activity against SARS-CoV-2 including intravenous (IV) RDV or administration of any SARS-CoV-2 (or COVID-19) vaccine
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive inhaled RDV 31 mg administered daily for 5 days.
Drug: Remdesivir (RDV)
Participants will receive inhaled RDV 31 mg administered daily for 3 days followed by placebo to match RDV daily for 2 days.
Drug: Remdesivir (RDV) · Drug: Placebo
Participants will receive placebo to match inhaled RDV in Part A daily for 5 days.
Drug: Placebo
Participants will receive inhaled RDV 62 mg administered daily for up to 5 days.
Drug: Remdesivir (RDV)
Participants will receive inhaled RDV 62 mg administered daily for up to 3 days followed by placebo to match RDV daily for 2 days.
Drug: Remdesivir (RDV) · Drug: Placebo
Participants will receive placebo to match inhaled RDV in Part B daily for 5 days.
Drug: Placebo
Participants will receive inhaled RDV 39 mg administered daily for 5 days.
Drug: Remdesivir (RDV)
Participants will receive placebo to match inhaled RDV in Part C daily for 5 days.
Drug: Placebo
Administered as an aerosolized solution
Also known as: GS-5734™
Administered as an aerosolized solution
Time-weighted Average Change From Baseline in Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load Through Day 7
Time-weighted average change in SARS-CoV-2 viral load was defined as area under the concentration versus time curve (AUC) of viral load change divided by time between baseline through Day 7.
Time frame: Baseline, Day 7
Time-weighted Average Change From Baseline in Oropharyngeal SARS-CoV-2 Viral Load Through Day 7
Time-weighted average change in SARS-CoV-2 viral load was defined as AUC of viral load change divided by time between baseline through Day 7.
Time frame: Baseline, Day 7
Time-weighted Average Change From Baseline in Saliva SARS-CoV-2 Viral Load Through Day 7
Time-weighted average change in SARS-CoV-2 viral load was defined as AUC of viral load change divided by time between baseline through Day 7.
Time frame: Baseline, Day 7
Percentage of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)
An adverse event (AE) was any untoward medical occurrence in a participant administered a study drug, which did not necessarily have a causal relationship with the treatment. AE was therefore any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of the study drug, whether or not considered related to the study drug. TEAEs: AE with an onset date on or after the study drug start date and no later than 30 days after study drug stop date; or any AE leading to study drug discontinuation.
Time frame: First dose date up to 5 days plus 30 days
Percentage of Participants With Treatment-Emergent Laboratory Abnormalities as Per Severity Grade
Treatment-emergent laboratory abnormalities were graded using the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 July 2017. Laboratory abnormalities were graded as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (life-threatening). Percentage of participants with any severity grade were reported.
Time frame: First dose date up to 5 days plus 30 days
Percentage of Participants With Treatment-Emergent Adverse Events Leading to Study Treatment Discontinuation
Time frame: First dose date up to 5 days plus 30 days
Number of Participants With All-Cause Medically Attended Visits (MAVs) or Death by Day 28
The composite outcome of all-cause MAVs (medical visits attended in person by the participant and a health care professional) or all-cause death by Study Day 28 were estimated using Kaplan-Meier methods by treatment group.
Time frame: Randomization up to Day 28
Number of Participants With COVID-19 Related MAVs or Death by Day 28
The composite outcome of COVID-19 related MAVs (medical visits attended in person by the participant and a health care professional) or all-cause death by Study Day 28 were estimated using Kaplan-Meier methods by treatment group.
Time frame: Randomization up to Day 28
Number of Participants With Hospitalization by Day 28
The composite of all-cause hospitalization was estimated using Kaplan-Meier methods by treatment group.
Time frame: Day 1 up to Day 28
Pharmacokinetic (PK) Parameter: AUC0-24h of Remdesivir (RDV) and Its Metabolites (GS-441524 and GS-704277) in Parts A and B
AUC0-24h was defined as the concentration of drug over time between time 0 to time 24 hours. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A \& Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.
Time frame: Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.
PK Parameter: AUClast of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B
AUClast was defined as the concentration of drug from time zero to the last observable concentration.Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A \& Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.
Time frame: Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.
PK Parameter: CLss/F of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B
CLss/F was defined as apparent oral clearance at steady state after administration of the drug. CLss/F = Dose/AUCtau, where "Dose" is the dose of the drug. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A \& Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.
Time frame: Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.
PK Parameter: t1/2 of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B
t1/2 was defined as the estimate of the terminal elimination half-life of the drug. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A \& Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.
Time frame: Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.
PK Parameter: Vz/F of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B
Vz/F was defined as the apparent volume of distribution of the drug. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A \& Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.
Time frame: Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.
PK Parameter: Cmax of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B
Cmax was defined as the maximum observed concentration of drug.Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A \& Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.
Time frame: Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.
PK Parameter: Tmax of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B
Tmax was defined as the time (observed time point) of Cmax. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A \& Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.
Time frame: Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.
PK Parameter: Clast of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B
Clast was defined as the last observable concentration of drug. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A \& Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.
Time frame: Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.
PK Parameter: Tlast of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B
Tlast was defined as the time (observed time point) of Clast. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A \& Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.
Time frame: Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.
PK Parameter: AUCtau of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B
AUCtau is defined as concentration of drug over time (the area under the concentration versus time curve over the dosing interval). Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A \& Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.
Time frame: Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.
PK Parameter: λz of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B
λz was defined as the terminal elimination rate constant, estimated by linear regression of the terminal elimination phase of the log plasma concentration of drug versus time curve of the drug. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A \& Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.
Time frame: Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.
PK Parameter: Ctau of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B
Ctau was defined as the observed drug concentration at the end of the dosing interval. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A \& Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.
Time frame: Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.
Change in Nasopharyngeal SARS-CoV-2 Viral Load From Baseline to Day 5
Time frame: Baseline, Day 5
Change in Oropharyngeal SARS-CoV-2 Viral Load From Baseline to Day 5
Time frame: Baseline, Day 5
Change in Saliva SARS-CoV-2 Viral Load From Baseline to Day 5
Time frame: Baseline, Day 5
Change in Nasopharyngeal SARS-CoV-2 Viral Load From Baseline to Day 7
Time frame: Baseline, Day 7
Change in Oropharyngeal SARS-CoV-2 Viral Load From Baseline to Day 7
Time frame: Baseline, Day 7
Change in Saliva SARS-CoV-2 Viral Load From Baseline to Day 7
Time frame: Baseline, Day 7
Change in Nasopharyngeal SARS-CoV-2 Viral Load From Baseline to Day 14 in Parts A and B
Time frame: Baseline, Day 14
Change in Oropharyngeal SARS-CoV-2 Viral Load From Baseline to Day 14 in Parts A and B
Time frame: Baseline, Day 14
Change in Saliva SARS-CoV-2 Viral Load From Baseline to Day 14 in Parts A and B
Time frame: Baseline, Day 14
Time to Negative Nasopharyngeal SARS-CoV-2 Polymerase Chain Reaction (PCR)
The time to negative nasopharyngeal SARS-CoV-2 PCR was defined as the number of days to first confirmed negative (first date of two consecutive dates achieving negative result) using nasopharyngeal sample. Time to negative nasopharyngeal SARS-CoV-2 PCR was calculated using Kaplan-Meier estimates.
Time frame: Baseline up to Day 17
Time to Negative Oropharyngeal SARS-CoV-2 Polymerase Chain Reaction (PCR)
The time to negative oropharyngeal SARS-CoV-2 PCR was defined as the number of days to first confirmed negative (first date of two consecutive dates achieving negative result) using an oropharyngeal sample. Time to negative oropharyngeal SARS-CoV-2 PCR was calculated using Kaplan-Meier estimates.
Time frame: Baseline up to Day 17
Time to Negative Saliva SARS-CoV-2 Polymerase Chain Reaction (PCR)
The time to saliva SARS-CoV-2 PCR was defined as the number of days to first confirmed negative (first date of two consecutive dates achieving negative result) using saliva sample. Time to negative saliva SARS-CoV-2 PCR was calculated using Kaplan-Meier estimates.
Time frame: Baseline up to Day 17
Time to Alleviation (Mild or Absent) of Baseline COVID-19 Symptoms as Reported on the COVID-19 Adapted InFLUenza Patient-Reported Outcome (FLU-PRO©) Questionnaire in Part C
The InFLUenza Patient-Reported Outcome (FLU-PRO©) is a 32-item patient-reported outcome questionnaire that assesses the severity of symptoms of influenza and influenza-like illness across six body systems. An additional two items can be added to assess changes in taste or smell, if the instrument is used to quantify symptoms in studies of COVID-19. Each domain scores ranges from 0 (symptom-free) to 4 (very severe symptoms). Higher scores on this scale represent higher disease severity. Alleviation is defined as symptom scores as 2 or higher at baseline are scored as 0 (absent) or 1 (mild) at post-baseline, and symptoms scored as 1 at baseline are scored as 0 at post-baseline, and for two consecutive days. Time to alleviation was calculated using Kaplan-Meier estimates.
Time frame: First dose date up to Day 14
Participants were enrolled at study sites in the United States. The first participant was screened on 14 September 2020. The last study visit occurred on 22 March 2021.
| Milestone | Remdesivir (RDV), Part A | RDV + Placebo, Part A | Placebo, Part A | RDV, Part B | RDV + Placebo, Part B | Placebo, Part B | RDV, Part C | Placebo, Part C |
|---|---|---|---|---|---|---|---|---|
| Started | 12 | 13 | 12 | 12 | 12 | 13 | 62 | 20 |
| Completed | 12 | 12 | 11 | 11 | 12 | 13 | 61 | 20 |
| Not completed | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrew consent | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Randomized, not treated | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 |
Time-weighted average change in SARS-CoV-2 viral load was defined as area under the concentration versus time curve (AUC) of viral load change divided by time between baseline through Day 7.
| log10 copies/mL | RDV, Part A | RDV + Placebo, Part A | Placebo, Part A | RDV, Part B | RDV + Placebo, Part B | Placebo, Part B | RDV, Part C | Placebo, Part C |
|---|---|---|---|---|---|---|---|---|
| Time-weighted Average Change From Baseline in Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load Through Day 7 | -2.04 ± 0.999 | -1.51 ± 0.812 | -1.24 ± 0.961 | -1.21 ± 1.108 | -1.42 ± 0.975 | -1.40 ± 0.796 | -1.91 ± 1.186 | -1.93 ± 1.284 |
Time-weighted average change in SARS-CoV-2 viral load was defined as AUC of viral load change divided by time between baseline through Day 7.
| log10 copies/mL | RDV, Part A | RDV + Placebo, Part A | Placebo, Part A | RDV, Part B | RDV + Placebo, Part B | Placebo, Part B | RDV, Part C | Placebo, Part C |
|---|---|---|---|---|---|---|---|---|
| Time-weighted Average Change From Baseline in Oropharyngeal SARS-CoV-2 Viral Load Through Day 7 | -1.10 ± 0.856 | -0.55 ± 0.868 | -1.39 ± 1.036 | -1.14 ± 1.133 | -0.85 ± 1.164 | -0.70 ± 0.902 | -0.83 ± 1.073 | -0.46 ± 1.152 |
Time-weighted average change in SARS-CoV-2 viral load was defined as AUC of viral load change divided by time between baseline through Day 7.
| log10 copies/mL | RDV, Part A | RDV + Placebo, Part A | Placebo, Part A | RDV, Part B | RDV + Placebo, Part B | Placebo, Part B | RDV, Part C | Placebo, Part C |
|---|---|---|---|---|---|---|---|---|
| Time-weighted Average Change From Baseline in Saliva SARS-CoV-2 Viral Load Through Day 7 | -0.80 ± 0.469 | -1.27 ± 0.877 | -0.49 ± 1.148 | -1.09 ± 1.497 | -0.61 ± 0.676 | -0.93 ± 0.678 | -1.25 ± 0.977 | -1.01 ± 1.096 |
An adverse event (AE) was any untoward medical occurrence in a participant administered a study drug, which did not necessarily have a causal relationship with the treatment. AE was therefore any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of the study drug, whether or not considered related to the study drug. TEAEs: AE with an onset date on or after the study drug start date and no later than 30 days after study drug stop date; or any AE leading to study drug discontinuation.
| percentage of participants | RDV, Part A | RDV + Placebo, Part A | Placebo, Part A | RDV, Part B | RDV + Placebo, Part B | Placebo, Part B | RDV, Part C | Placebo, Part C |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Experiencing Treatment Emergent Adverse Events (TEAEs) | 58.3 | 58.3 | 41.7 | 33.3 | 58.3 | 38.5 | 42.6 | 25.0 |
Treatment-emergent laboratory abnormalities were graded using the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 July 2017. Laboratory abnormalities were graded as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (life-threatening). Percentage of participants with any severity grade were reported.
| percentage of participants | RDV, Part A | RDV + Placebo, Part A | Placebo, Part A | RDV, Part B | RDV + Placebo, Part B | Placebo, Part B | RDV, Part C | Placebo, Part C |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Treatment-Emergent Laboratory Abnormalities as Per Severity Grade | 58.3 | 91.7 | 63.6 | 63.6 | 83.3 | 61.5 | 68.9 | 75.0 |
| percentage of participants | RDV, Part A | RDV + Placebo, Part A | Placebo, Part A | RDV, Part B | RDV + Placebo, Part B | Placebo, Part B | RDV, Part C | Placebo, Part C |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Treatment-Emergent Adverse Events Leading to Study Treatment Discontinuation | 0 | 0 | 8.3 | 0 | 0 | 0 | 1.6 | 0 |
The composite outcome of all-cause MAVs (medical visits attended in person by the participant and a health care professional) or all-cause death by Study Day 28 were estimated using Kaplan-Meier methods by treatment group.
| Participants | RDV, Part A | RDV + Placebo, Part A | Placebo, Part A | RDV, Part B | RDV + Placebo, Part B | Placebo, Part B | RDV, Part C | Placebo, Part C |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With All-Cause Medically Attended Visits (MAVs) or Death by Day 28 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 |
The composite outcome of COVID-19 related MAVs (medical visits attended in person by the participant and a health care professional) or all-cause death by Study Day 28 were estimated using Kaplan-Meier methods by treatment group.
| Participants | RDV, Part A | RDV + Placebo, Part A | Placebo, Part A | RDV, Part B | RDV + Placebo, Part B | Placebo, Part B | RDV, Part C | Placebo, Part C |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With COVID-19 Related MAVs or Death by Day 28 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 |
The composite of all-cause hospitalization was estimated using Kaplan-Meier methods by treatment group.
| Participants | RDV, Part A | RDV + Placebo, Part A | Placebo, Part A | RDV, Part B | RDV + Placebo, Part B | Placebo, Part B | RDV, Part C | Placebo, Part C |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Hospitalization by Day 28 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 0 |
AUC0-24h was defined as the concentration of drug over time between time 0 to time 24 hours. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A \& Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.
No measurements were reported for this outcome.
AUClast was defined as the concentration of drug from time zero to the last observable concentration.Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A \& Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.
No measurements were reported for this outcome.
CLss/F was defined as apparent oral clearance at steady state after administration of the drug. CLss/F = Dose/AUCtau, where "Dose" is the dose of the drug. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A \& Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.
No measurements were reported for this outcome.
t1/2 was defined as the estimate of the terminal elimination half-life of the drug. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A \& Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.
No measurements were reported for this outcome.
Vz/F was defined as the apparent volume of distribution of the drug. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A \& Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.
No measurements were reported for this outcome.
Cmax was defined as the maximum observed concentration of drug.Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A \& Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.
No measurements were reported for this outcome.
Tmax was defined as the time (observed time point) of Cmax. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A \& Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.
No measurements were reported for this outcome.
Clast was defined as the last observable concentration of drug. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A \& Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.
No measurements were reported for this outcome.
Tlast was defined as the time (observed time point) of Clast. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A \& Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.
No measurements were reported for this outcome.
AUCtau is defined as concentration of drug over time (the area under the concentration versus time curve over the dosing interval). Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A \& Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.
No measurements were reported for this outcome.
λz was defined as the terminal elimination rate constant, estimated by linear regression of the terminal elimination phase of the log plasma concentration of drug versus time curve of the drug. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A \& Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.
No measurements were reported for this outcome.
Ctau was defined as the observed drug concentration at the end of the dosing interval. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A \& Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.
No measurements were reported for this outcome.
| log10 copies/mL | RDV, Part A | RDV + Placebo, Part A | Placebo, Part A | RDV, Part B | RDV + Placebo, Part B | Placebo, Part B | RDV, Part C | Placebo, Part C |
|---|---|---|---|---|---|---|---|---|
| Change in Nasopharyngeal SARS-CoV-2 Viral Load From Baseline to Day 5 | -2.44 ± 1.240 | -1.67 ± 0.992 | -1.78 ± 1.357 | -1.53 ± 1.063 | -1.68 ± 1.475 | -2.09 ± 1.052 | -2.01 ± 1.402 | -2.06 ± 1.321 |
| log10 copies/mL | RDV, Part A | RDV + Placebo, Part A | Placebo, Part A | RDV, Part B | RDV + Placebo, Part B | Placebo, Part B | RDV, Part C | Placebo, Part C |
|---|---|---|---|---|---|---|---|---|
| Change in Oropharyngeal SARS-CoV-2 Viral Load From Baseline to Day 5 | -1.24 ± 0.957 | -0.88 ± 0.839 | -1.26 ± 1.418 | -1.29 ± 1.457 | -1.13 ± 1.394 | -1.10 ± 0.988 | -0.92 ± 1.213 | -0.66 ± 1.581 |
| log10 copies/mL | RDV, Part A | RDV + Placebo, Part A | Placebo, Part A | RDV, Part B | RDV + Placebo, Part B | Placebo, Part B | RDV, Part C | Placebo, Part C |
|---|---|---|---|---|---|---|---|---|
| Change in Saliva SARS-CoV-2 Viral Load From Baseline to Day 5 | -0.99 ± 0.562 | -1.26 ± 1.288 | -0.77 ± 1.449 | -1.60 ± 1.443 | -0.31 ± 0.708 | -0.92 ± 1.040 | -1.36 ± 1.056 | -1.15 ± 0.962 |
| log10 copies/mL | RDV, Part A | RDV + Placebo, Part A | Placebo, Part A | RDV, Part B | RDV + Placebo, Part B | Placebo, Part B | RDV, Part C | Placebo, Part C |
|---|---|---|---|---|---|---|---|---|
| Change in Nasopharyngeal SARS-CoV-2 Viral Load From Baseline to Day 7 | -3.05 ± 1.225 | -2.12 ± 1.051 | -2.09 ± 1.331 | -1.80 ± 1.389 | -2.30 ± 1.257 | -2.34 ± 1.873 | -2.64 ± 1.299 | -2.62 ± 1.555 |
| log10copies/mL | RDV, Part A | RDV + Placebo, Part A | Placebo, Part A | RDV, Part B | RDV + Placebo, Part B | Placebo, Part B | RDV, Part C | Placebo, Part C |
|---|---|---|---|---|---|---|---|---|
| Change in Oropharyngeal SARS-CoV-2 Viral Load From Baseline to Day 7 | -1.76 ± 1.113 | -0.40 ± 1.049 | -1.98 ± 0.971 | -1.73 ± 1.513 | -1.08 ± 1.160 | -1.27 ± 0.845 | -1.07 ± 1.122 | -0.62 ± 1.606 |
| log10 copies/mL | RDV, Part A | RDV + Placebo, Part A | Placebo, Part A | RDV, Part B | RDV + Placebo, Part B | Placebo, Part B | RDV, Part C | Placebo, Part C |
|---|---|---|---|---|---|---|---|---|
| Change in Saliva SARS-CoV-2 Viral Load From Baseline to Day 7 | -1.28 ± 1.102 | -1.24 ± 2.108 | -0.62 ± 1.406 | -1.91 ± 1.667 | -0.99 ± 0.943 | -1.53 ± 1.553 | -1.69 ± 1.302 | -1.31 ± 1.752 |
| log10 copies/mL | RDV, Part A | RDV + Placebo, Part A | Placebo, Part A | RDV, Part B | RDV + Placebo, Part B | Placebo, Part B |
|---|---|---|---|---|---|---|
| Change in Nasopharyngeal SARS-CoV-2 Viral Load From Baseline to Day 14 in Parts A and B | -4.11 ± 1.304 | -2.96 ± 1.475 | -3.31 ± 1.198 | -2.82 ± 1.888 | -2.86 ± 1.837 | -3.41 ± 1.442 |
| log10 copies/mL | RDV, Part A | RDV + Placebo, Part A | Placebo, Part A | RDV, Part B | RDV + Placebo, Part B | Placebo, Part B |
|---|---|---|---|---|---|---|
| Change in Oropharyngeal SARS-CoV-2 Viral Load From Baseline to Day 14 in Parts A and B | -2.46 ± 0.908 | -1.47 ± 0.841 | -2.36 ± 0.951 | -1.46 ± 1.194 | -1.95 ± 1.283 | -2.05 ± 1.092 |
| log10 copies/mL | RDV, Part A | RDV + Placebo, Part A | Placebo, Part A | RDV, Part B | RDV + Placebo, Part B | Placebo, Part B |
|---|---|---|---|---|---|---|
| Change in Saliva SARS-CoV-2 Viral Load From Baseline to Day 14 in Parts A and B | -2.58 ± 1.413 | -2.27 ± 1.136 | -1.78 ± 0.618 | -2.30 ± 1.505 | -2.11 ± 1.171 | -3.53 ± 1.253 |
The time to negative nasopharyngeal SARS-CoV-2 PCR was defined as the number of days to first confirmed negative (first date of two consecutive dates achieving negative result) using nasopharyngeal sample. Time to negative nasopharyngeal SARS-CoV-2 PCR was calculated using Kaplan-Meier estimates.
| days | RDV, Part A | RDV + Placebo, Part A | Placebo, Part A | RDV, Part B | RDV + Placebo, Part B | Placebo, Part B | RDV, Part C | Placebo, Part C |
|---|---|---|---|---|---|---|---|---|
| Time to Negative Nasopharyngeal SARS-CoV-2 Polymerase Chain Reaction (PCR) | NA (NA to NA) | 17.0 (16.0 to 17.0) | NA (NA to NA) | 16.0 (7.0 to 16.0) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
The time to negative oropharyngeal SARS-CoV-2 PCR was defined as the number of days to first confirmed negative (first date of two consecutive dates achieving negative result) using an oropharyngeal sample. Time to negative oropharyngeal SARS-CoV-2 PCR was calculated using Kaplan-Meier estimates.
| days | RDV, Part A | RDV + Placebo, Part A | Placebo, Part A | RDV, Part B | RDV + Placebo, Part B | Placebo, Part B | RDV, Part C | Placebo, Part C |
|---|---|---|---|---|---|---|---|---|
| Time to Negative Oropharyngeal SARS-CoV-2 Polymerase Chain Reaction (PCR) | 14.0 (5.0 to 15.0) | 15.0 (4.0 to 16.0) | 13.0 (7.0 to NA) | 5.0 (2.0 to 15.0) | NA (NA to NA) | 14.0 (5.0 to 15.0) | NA (NA to NA) | NA (NA to NA) |
The time to saliva SARS-CoV-2 PCR was defined as the number of days to first confirmed negative (first date of two consecutive dates achieving negative result) using saliva sample. Time to negative saliva SARS-CoV-2 PCR was calculated using Kaplan-Meier estimates.
| days | RDV, Part A | RDV + Placebo, Part A | Placebo, Part A | RDV, Part B | RDV + Placebo, Part B | Placebo, Part B | RDV, Part C | Placebo, Part C |
|---|---|---|---|---|---|---|---|---|
| Time to Negative Saliva SARS-CoV-2 Polymerase Chain Reaction (PCR) | NA (NA to NA) | 17.0 (13.0 to 17.0) | NA (NA to NA) | 16.0 (7.0 to 16.0) | 14.0 (3.0 to 15.0) | NA (NA to NA) | NA (NA to NA) | 16.0 (7.0 to 16.0) |
The InFLUenza Patient-Reported Outcome (FLU-PRO©) is a 32-item patient-reported outcome questionnaire that assesses the severity of symptoms of influenza and influenza-like illness across six body systems. An additional two items can be added to assess changes in taste or smell, if the instrument is used to quantify symptoms in studies of COVID-19. Each domain scores ranges from 0 (symptom-free) to 4 (very severe symptoms). Higher scores on this scale represent higher disease severity. Alleviation is defined as symptom scores as 2 or higher at baseline are scored as 0 (absent) or 1 (mild) at post-baseline, and symptoms scored as 1 at baseline are scored as 0 at post-baseline, and for two consecutive days. Time to alleviation was calculated using Kaplan-Meier estimates.
| days | RDV, Part C | Placebo, Part C |
|---|---|---|
| Time to Alleviation (Mild or Absent) of Baseline COVID-19 Symptoms as Reported on the COVID-19 Adapted InFLUenza Patient-Reported Outcome (FLU-PRO©) Questionnaire in Part C | NA (NA to NA) | NA (NA to NA) |
Collected over Adverse Events: First dose date up to 5 days plus 30 days All-Cause Mortality: Randomization date up to 35 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| RDV, Part A | 0/12 (0%) | 0/12 (0%) | 7/12 (58.3%) |
| RDV + Placebo, Part A | 0/13 (0%) | 1/12 (8.3%) | 7/12 (58.3%) |
| Placebo, Part A | 0/12 (0%) | 2/12 (16.7%) | 5/12 (41.7%) |
| RDV, Part B | 0/12 (0%) | 0/12 (0%) | 4/12 (33.3%) |
| RDV + Placebo, Part B | 0/12 (0%) | 1/12 (8.3%) | 6/12 (50%) |
| Placebo, Part B | 0/13 (0%) | 1/13 (7.7%) | 5/13 (38.5%) |
| RDV, Part C | 0/62 (0%) | 0/61 (0%) | 24/61 (39.3%) |
| Placebo, Part C | 0/20 (0%) | 0/20 (0%) | 5/20 (25%) |
| Event | RDV, Part A | RDV + Placebo, Part A | Placebo, Part A | RDV, Part B | RDV + Placebo, Part B | Placebo, Part B | RDV, Part C | Placebo, Part C |
|---|---|---|---|---|---|---|---|---|
| Acute myocardial infarctionCardiac disorders | 0/12 | 0/12 | 1/12 | 0/12 | 0/12 | 0/13 | 0/61 | 0/20 |
| Incarcerated herniaGeneral disorders | 0/12 | 0/12 | 0/12 | 0/12 | 1/12 | 0/13 | 0/61 | 0/20 |
| Covid-19 pneumoniaInfections and infestations | 0/12 | 1/12 | 1/12 | 0/12 | 0/12 | 1/13 | 0/61 | 0/20 |
| Event | RDV, Part A | RDV + Placebo, Part A | Placebo, Part A | RDV, Part B | RDV + Placebo, Part B | Placebo, Part B | RDV, Part C | Placebo, Part C |
|---|---|---|---|---|---|---|---|---|
| DizzinessNervous system disorders | 3/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/13 | 5/61 | 1/20 |
| VomitingGastrointestinal disorders | 0/12 | 2/12 | 0/12 | 0/12 | 0/12 | 0/13 | 0/61 | 0/20 |
| Aspartate aminotransferase increasedInvestigations | 0/12 | 0/12 | 2/12 | 0/12 | 0/12 | 0/13 | 1/61 | 0/20 |
| Lacrimation increasedEye disorders | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/13 | 1/61 | 2/20 |
| SneezingRespiratory, thoracic and mediastinal disorders | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/13 | 2/61 | 2/20 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/12 | 1/12 | 0/12 | 1/12 | 1/12 | 0/13 | 6/61 | 1/20 |
| LeukocytosisBlood and lymphatic system disorders | 0/12 | 0/12 | 1/12 | 0/12 | 0/12 | 0/13 | 0/61 | 0/20 |
| NeutropeniaBlood and lymphatic system disorders | 0/12 | 1/12 | 0/12 | 0/12 | 0/12 | 0/13 | 0/61 | 0/20 |
| NeutrophiliaBlood and lymphatic system disorders | 0/12 | 0/12 | 1/12 | 0/12 | 0/12 | 1/13 | 0/61 | 0/20 |
| TinnitusEar and labyrinth disorders | 0/12 | 0/12 | 1/12 | 0/12 | 0/12 | 0/13 | 0/61 | 0/20 |
The Safety Analysis Set included all participants who were randomized into the study and received at least 1 dose of study treatment.
| Age, Customized(Participants) | RDV, Part A | RDV + Placebo, Part A | Placebo, Part A | RDV, Part B | RDV + Placebo, Part B | Placebo, Part B | RDV, Part C | Placebo, Part C | Total |
|---|---|---|---|---|---|---|---|---|---|
| < 60 years | 10 | 11 | 9 | 12 | 10 | 12 | 55 | 15 | 134 |
| ≥ 60 years | 2 | 1 | 3 | 0 | 2 | 1 | 6 | 5 | 20 |
| Sex: Female, Male(Participants) | RDV, Part A | RDV + Placebo, Part A | Placebo, Part A | RDV, Part B | RDV + Placebo, Part B | Placebo, Part B | RDV, Part C | Placebo, Part C | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 8 | 5 | 4 | 7 | 5 | 6 | 34 | 8 | 77 |
| Male | 4 | 7 | 8 | 5 | 7 | 7 | 27 | 12 | 77 |
| Ethnicity (NIH/OMB)(Participants) | RDV, Part A | RDV + Placebo, Part A | Placebo, Part A | RDV, Part B | RDV + Placebo, Part B | Placebo, Part B | RDV, Part C | Placebo, Part C | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 6 | 3 | 3 | 2 | 6 | 4 | 40 | 14 | 78 |
| Not Hispanic or Latino | 6 | 9 | 9 | 10 | 4 | 9 | 21 | 6 | 74 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 2 |
| Race/Ethnicity, Customized(Participants) | RDV, Part A | RDV + Placebo, Part A | Placebo, Part A | RDV, Part B | RDV + Placebo, Part B | Placebo, Part B | RDV, Part C | Placebo, Part C | Total |
|---|---|---|---|---|---|---|---|---|---|
| Race — Asian | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 2 |
| Race — Black | 0 | 0 | 0 | 0 | 1 | 1 | 12 | 2 | 16 |
| Race — White | 11 | 9 | 10 | 11 | 10 | 12 | 47 | 16 | 126 |
| Race — American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 |
| Race — Not Permitted | 1 | 2 | 1 | 0 | 1 | 0 | 0 | 0 | 5 |
| Race — Other | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 3 |
| SARS-CoV-2 Viral load - Nasopharyngeal(log10 copies/mL) | RDV, Part A | RDV + Placebo, Part A | Placebo, Part A | RDV, Part B | RDV + Placebo, Part B | Placebo, Part B | RDV, Part C | Placebo, Part C | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 7.29 ± 1.901 | 6.56 ± 1.065 | 6.81 ± 1.065 | 5.23 ± 1.980 | 6.41 ± 1.883 | 7.09 ± 1.288 | 5.69 ± 2.004 | 5.76 ± 1.839 | 6.14 ± 1.859 |
| SARS-CoV-2 Viral load - Oropharyngeal(log10 copies/mL) | RDV, Part A | RDV + Placebo, Part A | Placebo, Part A | RDV, Part B | RDV + Placebo, Part B | Placebo, Part B | RDV, Part C | Placebo, Part C | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 5.69 ± 0.959 | 4.74 ± 1.225 | 5.57 ± 1.275 | 4.40 ± 1.772 | 5.16 ± 1.356 | 4.79 ± 1.377 | 4.38 ± 1.610 | 3.94 ± 1.203 | 4.64 ± 1.505 |
| SARS-CoV-2 Viral load - Saliva(log10 copies/mL) | RDV, Part A | RDV + Placebo, Part A | Placebo, Part A | RDV, Part B | RDV + Placebo, Part B | Placebo, Part B | RDV, Part C | Placebo, Part C | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 5.56 ± 1.682 | 5.19 ± 1.312 | 4.77 ± 1.218 | 5.15 ± 2.048 | 4.77 ± 1.281 | 5.60 ± 1.074 | 4.93 ± 1.785 | 4.57 ± 1.559 | 5.00 ± 1.613 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2020 to primary completion in Feb 2021, 5 months.
Results were first posted in Mar 2022, 1 year after primary completion.
Of 80 industry-sponsored phase 1/2 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 5 months is below that.
Counting every sponsor, half of 187 studies reached it within 11 months; a quarter within 4 and three quarters within 20.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Remdesivir